Articles tagged with Chemotherapy
A standard chemotherapy regimen has been shown to increase survival rates in patients with limited-stage Hodgkin's lymphoma. This finding is significant, as it may lead to reduced radiation exposure and lower risk of long-term complications.
A new analysis found that breast cancer survivors may experience mental abilities problems several years after treatment, regardless of therapy type. Chemotherapy was linked to persistent cognitive issues, while radiation also caused similar problems in some cases.
A multicenter study found ruxolinitib significantly reduces symptoms of myelofibrosis, including pain and enlarged spleen, compared to placebo. The study also showed ruxolinitib is more effective than best available chemotherapies in reducing symptoms.
A team of researchers identified APNG as a contributor to GBM resistance to temozolomide, with high nuclear expression correlating to poorer survival. Monitoring APNG levels may provide insight into patient response to temozolomide treatment.
A new treatment using leukemia patients' own infection-fighting cells appears to protect them from infections and cancer recurrence after fludarabine-based chemotherapy. With a restored immune system, patients can stop taking prophylactic antibiotics and may have prolonged progression-free survival.
A randomized Phase III study found that repeated rituximab treatment at disease progression is just as effective as ongoing maintenance therapy in managing follicular lymphoma. The study suggests that an as-needed approach to treatment may be the preferred option for patients with low-tumor-burden FL, reducing healthcare costs and impr...
A large study showed that obese patients have poorer long-term outcomes than normal-weight patients when not treated with trastuzumab. Adding trastuzumab to treatment may potentially equalize disease-free survival rates among all patient groups.
Breast cancer mortality is higher in Hispanic women compared to non-Hispanic white women, with a 20% increased risk of death. The ethnic disparity may be attributed to tumor phenotypes less responsive to chemotherapy, which affects long-term survival rates.
Researchers at Mayo Clinic have found a combination of drugs that destroys 70% of chemotherapy-resistant ovarian cancer cells. The discovery highlights the role of molecule RhoB in tumor response and may help identify patients who benefit from this therapy.
A German study found no improvement in disease-free survival among breast cancer patients treated with dose-dense chemotherapy and oral ibandronate. The results contradict previous studies, which showed benefits in postmenopausal patients receiving zoledronic acid or endocrine treatment.
A significant number of women with breast cancer are not receiving guideline-recommended adjuvant treatment. The research found that socioeconomic factors such as poverty, insurance status, and education level significantly contribute to this disparity. Women from high-poverty areas were less likely to receive guideline therapy, highli...
A new triple drug combination has been shown to increase tumour eradication in HER2-positive breast cancer by more than half, with 46% of patients achieving a pathological complete response. The treatment was well-tolerated and did not significantly increase side effects or cardiac risk compared to standard therapy.
Researchers found that dopamine injections improved blood flow to tumors, doubling the concentration of an anticancer drug and increasing its effectiveness. Dopamine also normalized the structure of abnormal tumor blood vessels, a condition typically associated with reduced chemotherapy and radiation therapy effectiveness.
A small pilot study suggests that acupuncture can improve nerve signaling and alleviate symptoms of chemotherapy-induced peripheral neuropathy in cancer patients. The treatment showed positive effects on nerve conduction studies and patient-reported improvements, sparking hope for further investigation into its potential benefits.
A meta-analysis of 123 randomised trials involving 100,000 women with breast cancer shows that modern chemotherapy regimens reduce breast cancer mortality by around one-third compared to no chemotherapy. The findings suggest that standard 1980s chemotherapy regimens could produce a reduction of almost a quarter in breast cancer mortality.
A follow-up study by Moffitt Cancer Center researchers found that patients who received chemotherapy for breast cancer may experience prolonged fatigue years after treatment. This contradicts prior research and has important implications for patient education and fatigue monitoring during follow-up.
Four US clinical centers have begun providing access to Novocure's Tumor Treating Fields (TTFields) device for treating recurrent GBM, a deadly brain tumor. The device has shown clinical efficacy comparable to active chemotherapies with better quality of life.
A UK study published in The Lancet found that a surveillance-only policy can be effective for women with high human chorionic gonadotropin (hCG) concentrations after molar pregnancies. Nearly all patients will spontaneously remit, avoiding unnecessary chemotherapy and its side effects.
A new study reveals that more intensive chemotherapy regimens significantly improve event-free survival and reduce mortality in younger patients with aggressive diffuse large B-cell lymphoma. Younger patients who received dose-intensive chemotherapy had an 81% event-free survival rate, compared to 67% for those on standard treatment.
Despite advancements in genetic profiling, breast cancer treatment remains non-personalized due to limited robust prognostic and predictive factors. Standard gene expression profiling has shown limitations in predicting chemotherapy benefit and prognosis for certain disease subsets.
A study published in Archives of Neurology found that breast cancer survivors who received chemotherapy demonstrated reduced activation in key brain areas and poorer executive function. The researchers also discovered that negative effects of chemotherapy may be exacerbated by factors such as age and educational level.
A phase III trial found that concurrent chemo-radiotherapy significantly improved the 5-year overall survival of patients with stage II nasopharyngeal carcinoma. The treatment regimen resulted in higher progression-free and distant metastasis-free survival rates compared to radiation alone.
Patients with high EGFR expression have a survival advantage when treated with cetuximab plus chemotherapy, living up to 12 months on average. In contrast, those with low EGFR expression show no difference in overall survival.
Scientists at Dana-Farber Cancer Institute have developed a test that can predict how effective chemotherapy agents will be against a patient's tumor cells. By measuring the proximity of cancer cells to self-destruction, researchers found that tumors with higher mitochondrial priming are more susceptible to chemotherapy.
Researchers have identified a gene variant associated with an increased risk of leukemia relapse in young patients treated with E. coli asparaginase, a common chemotherapy drug. This discovery may lead to personalized treatment approaches based on genetic profiles.
A phase 2 trial shows that combining standard chemotherapy with a new cancer vaccine enhances treatment effect and slows disease progression in NSCLC patients. The vaccine stimulates an immune response against the MUC1 protein, which is overexpressed in 60% of NSCLCs.
A new study suggests that Rituximab treatment can lead to significant improvement in CFS symptoms, potentially revealing a new direction for CFS research. The anti-CD20 antibody depletes B-lymphocytes, which are thought to be crucial in the disease's progression.
Researchers developed a simplified lab technique for measuring polymer characteristics using magnets, validating decades-old Nobel-Prize-winning theory. The new method uses magnetic tweezers to measure the structure and other critical parameters of long polymer molecules like polyethylene glycol.
A study comparing parental and healthcare professional preferences reveals a significant disparity in decision-making regarding palliative care for children with cancer. Parents favor aggressive chemotherapy, while healthcare professionals prefer supportive care.
A study found that women with BRCA2 genetic mutations experienced significantly better overall survival rates (61") compared to those without the mutation (25"). Additionally, BRCA2-mutated patients demonstrated longer progression-free survival durations and higher primary chemotherapy sensitivity rates
A new drug combination of fludarabine and alemtuzumab significantly increases progression-free survival and prolongs the lives of patients with chronic lymphocytic leukemia (CLL). The treatment spares patients from toxicities and offers a more convenient dosing schedule.
Researchers at University of California, San Diego, have made a groundbreaking discovery blocking the progression of lung fibrosis in mice. By targeting a specific phosphorylation pathway, they found that it may contribute to the development of lung injury and fibrosis.
A UNC-led study shows that patients with high-risk non-melanoma skin carcinomas of the head and neck may benefit from concomitant radiotherapy and chemotherapy, achieving better outcomes compared to radiation alone. The study provides preliminary data on the feasibility of combining chemotherapy with radiotherapy.
G-Zero Therapeutics, a UNC spin-off, has received a $3 million Small Business Innovation Research Grant to commercialize technology protecting patients from cellular damage caused by radiation or cancer chemotherapy. The grant will fund the development of treatments for bone marrow toxicity resulting from radiation and chemotherapy.
Researchers discovered that frequent low-dose administration of chemotherapy medicine topotecan can slow prostate cancer growth without causing side effects. This 'metronomic dosing' alters the cellular activity of the drug, offering a promising new approach to treating slowly growing tumors.
Researchers tested a combination of oral drug sorafenib and microbead chemotherapy directly into tumors in advanced liver cancer patients. The treatment showed promise with no increased side effects compared to existing therapies.
Researchers found a way to shut down pumps on breast cancer cells' surface that reject chemotherapy drugs, allowing the drugs to penetrate and kill the cells. Activating heat-shock protein Hsp27 forces the pump-action protein P-gp to decrease, making the cells more sensitive to chemotherapy drug Doxorubicin.
A newly identified DNA repair defect may leave some young leukemia patients less likely to benefit from chemotherapy, increasing the risk of relapse. The study found low levels of a key protein and missing regulatory genes in leukemia cells, suggesting a potential new marker for high-risk patients.
A study found that children born after mothers received chemotherapy during pregnancy had normal cognitive and cardiac development, but those born preterm were more likely to experience developmental delays. Researchers recommend continuing cancer treatment during pregnancy unless preterm delivery can be prevented.
A major UK trial found that giving radiotherapy between or during chemotherapy cycles significantly reduces the risk of breast cancer recurring in the breast or chest wall. The treatment, known as synchronous chemoradiation, has minimal adverse side-effects and no detrimental effect on quality of life.
A Phase II study showed that trastuzumab emtansine (T-DM1) significantly delayed breast cancer progression, improving patients' lives with fewer side effects. The treatment improved time to disease worsening by 41% compared to standard docetaxel chemotherapy plus trastuzumab.
Researchers at Johns Hopkins University have developed a protein switch that instructs cancer cells to produce their own anti-cancer medication. The goal is to deploy a new type of weapon that causes cancer cells to self-destruct while sparing healthy tissue.
A new type of nanoparticle has been developed to deliver chemotherapy drugs more effectively, with a high drug loading capacity and controlled release. The nanoparticle demonstrated significant growth inhibition of pancreatic tumors, showing up to three times higher therapeutic efficacy than traditional chemotherapy drugs.
Researchers at Case Western Reserve University are studying whether an over-the-counter medication, Glutamine, can ease chemotherapy side effects for people with blood and bone marrow cancers. The study aims to determine if Glutamine will interfere with chemotherapy or yield no benefits for patients diagnosed with multiple myeloma.
A University of Chicago Medical Center expert argues that taking oral anti-cancer medications with food could reduce overdose risks and save patients money. The medication ZYTIGA is a prime example, where taking it with food can increase its effectiveness by up to tenfold.
Researchers found that soy peptide lunasin binds to receptors in highly metastatic colon cancer cells, preventing them from attaching to the liver. Combining lunasin with chemotherapy drug oxaliplatin resulted in a sixfold reduction in new tumor sites.
Researchers at Moffitt Cancer Center have identified a molecular pathway that may play a key role in the evolution of chemotherapy resistance in ovarian cancer. The 'BCL2 antagonist of cell death' (BAD) pathway shows promise as a biomarker to identify patients with high-risk ovarian cancer and potentially reverse chemo-resistance.
Dr. John G. Bartlett has been recognized for his outstanding contributions to antimicrobial chemotherapy and infectious diseases research. He is a pioneer in understanding emerging problems and innovations in the field.
Researchers have successfully delivered chemotherapy to cancer cells inside tiny microparticles, reducing ovarian cancer tumours by 65 times more than traditional methods. The 'Trojan Horse' approach uses a special protein called CD95 to hijack cancer cells and deliver the chemotherapy cargo.
Researchers at University Medical Center Utrecht discovered that fish oil supplements containing omega-3 and omega-6 fatty acids can induce resistance to a broad spectrum of chemotherapies. The study found that the body's own protective substances, which are also present in fish oil, can block the effect of chemotherapy.
Research from the University of Gothenburg found that chemotherapy can cause significant language difficulties in cancer patients, including trouble with sentence completion and word order. The study used a unique questionnaire to assess everyday life difficulties, resulting in an 80% response rate and a long follow-up period.
Researchers at Penn State University have invented a method using magnetic fields to purify hybrid nanoparticles, which are composed of two or more kinds of materials. This technique will help improve drug-delivery systems, drug-targeting technologies, medical-imaging technologies, and electronic information-storage devices.
Tiny oxygen generators implanted in tumors boost killing power of radiation and chemotherapy, treating hypoxic solid tumors. The technology has shown promising results in shrinking tumors faster than those without devices.
A new study published in Neurology found that brain tumor patients who take valproic acid on top of standard treatment may live longer than those taking other epilepsy medications. The study showed an average three-month increase in survival for patients receiving valproic acid, but also noted increased risk of bleeding and infection.
A new study found that MRI-assessed tumor responses to neoadjuvant therapy can predict survival among patients with advanced rectal cancer. The findings suggest that using MRI prior to surgery may help change the course of patient care, enabling physicians to choose a more effective chemotherapy drug or avoid surgery in some cases.
A recent UCSF study analyzes the long-term effects of chemotherapy on women's reproductive health, finding that younger women are more likely to experience early menopause and infertility. The research provides new insights for patients and clinicians, enabling more strategic and personalized counseling about fertility preservation.
A U-M study found that nearly 17% of oncology nurses in outpatient settings were unintentionally exposed to chemotherapy drugs on their skin or eyes. The study emphasizes the importance of implementing nurse safety measures and adhering to national guidelines for preventing these incidents.
A new study published in The Lancet found that platinum-based doublet chemotherapy is associated with improved survival rates for elderly patients with non-small-cell lung cancer. The treatment showed better results compared to monotherapy in patients over 70 years old, suggesting a potential shift in the current treatment strategy for...
The OPTIMAL trial found erlotinib significantly prolonged median progression-free survival compared to chemotherapy (13.1 months vs 4.6 months). Serious treatment-related side effects were also more common in patients receiving chemotherapy.
Researchers found that temporarily suppressing ovarian function with triptorelin reduced the occurrence of early menopause induced by chemotherapy among premenopausal women with breast cancer. The treatment resulted in a 17% lower rate of early menopause compared to chemotherapy alone.